Liver Int

• 

  Publication Venue For

  • An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution..  42:1605-1617. 2022
  • Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries..  42:1323-1329. 2022
  • Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI..  42:1158-1172. 2022
  • The relationship between frailty and cirrhosis etiology: From the Functional Assessment in Liver Transplantation (FrAILT) Study..  41:2467-2473. 2021
  • Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury..  41:2214-2227. 2021
  • Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles..  41:1884-1893. 2021
  • Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis..  41:996-1011. 2021
  • Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study..  41:692-704. 2021
  • Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation..  40:830-843. 2020
  • The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury..  39:401-410. 2019
  • Expanding our toolkit to better identify drug-induced liver injury in electronic medical records..  38:585-587. 2018
  • Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury..  37:1723-1730. 2017
  • The diversity and plasticity of adult hepatic progenitor cells and their niche..  37:1260-1271. 2017
  • The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?.  36:1490-1497. 2016
  • Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease..  36:1213-1220. 2016
  • Liver injury from nonsteroidal anti-inflammatory drugs in the United States..  36:603-609. 2016
  • Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)..  35:1623-1632. 2015
  • Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C..  35:429-437. 2015
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy..  34:1018-1024. 2014
  • Association of age-dependent liver injury and fibrosis with immune cell populations..  33:1175-1186. 2013
  • Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease..  33:1062-1070. 2013
  • Macrophage-derived Hedgehog ligands promotes fibrogenic and angiogenic responses in human schistosomiasis mansoni..  33:149-161. 2013
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C..  29:1350-1355. 2009
  • Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice..  29:1262-1272. 2009
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure..  29:481-482. 2009
  • Hepatic fat and adenosine triphosphate measurement in overweight and obese adults using 1H and 31P magnetic resonance spectroscopy..  28:675-681. 2008
  • Successful management of chylous ascites after living donor liver transplantation with somatostatin..  28:143-145. 2008